Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Background There are few validated fluid biomarkers in frontotemporal dementia (FTD). Glial fibrillary acidic protein (GFAP) is a measure of astrogliosis, a known pathological process of FTD, but has yet to be explored as potential biomarker. Methods Plasma GFAP and neurofilament light chain (NfL) concentration were measured in 469 individuals enrolled in the Genetic FTD Initiative: 114 C9orf72 expansion carriers (74 presymptomatic, 40 symptomatic), 119 GRN mutation carriers (88 presymptomatic, 31 symptomatic), 53 MAPT mutation carriers (34 presymptomatic, 19 symptomatic) and 183 non-carrier controls. Biomarker measures were compared between groups using linear regression models adjusted for age and sex with family membership included as random effect. Participants underwent standardised clinical assessments including the Mini-Mental State Examination (MMSE), Frontotemporal Lobar Degeneration-Clinical Dementia Rating scale and MRI. Spearman’s correlation coefficient was used to investigate the relationship of plasma GFAP to clinical and imaging measures. Results Plasma GFAP concentration was significantly increased in symptomatic GRN mutation carriers (adjusted mean difference from controls 192.3 pg/mL, 95% CI 126.5 to 445.6), but not in those with C9orf72 expansions (9.0, –61.3 to 54.6), MAPT mutations (12.7, –33.3 to 90.4) or the presymptomatic groups. GFAP concentration was significantly positively correlated with age in both controls and the majority of the disease groups, as well as with NfL concentration. In the presymptomatic period, higher GFAP concentrations were correlated with a lower cognitive score (MMSE) and lower brain volume, while in the symptomatic period, higher concentrations were associated with faster rates of atrophy in the temporal lobe. Conclusions Raised GFAP concentrations appear to be unique to GRN -related FTD, with levels potentially increasing just prior to symptom onset, suggesting that GFAP may be an important marker of proximity to onset, and helpful for forthcoming therapeutic prevention trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A medium to strong positive correlation between serum GFAP and serum NfL was observed in all diagnostic groups, and has been previously described in controls, FTD and AD [83, 84].”
From A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias (2022) · cites this paper as [84]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, GFAP elevations have been reported in frontotemporal dementia39, traumatic brain injury40, multiple sclerosis41 and inflammatory central nervous system diseases42.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, some investigators [8, 11, 14] but not others [9, 21–23] found that blood GFAP concentrations correlate with clinical markers of disease severity in participants with FTD.”
From Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationClinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,359
Self-citationReactive Astrocytes: Production, Function, and Therapeutic Potential
Liddelow, S. A., & Barres, B. A. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.006 · Cited by 2,336
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049 · cited 1×
“27 In neurodegeneration, increased GFAP concentrations in biofluid have been reported in Alzheimer’s disease 30 (in both CSF 17 19 and serum 19 ) and amyotrophic lateral sclerosis 18 .”
Self-citationCriteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Self-citationDifferential aging of the brain: Patterns, cognitive correlates and modifiers
Raz, N., & Rodrigue, K. M. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.07.001 · Cited by 1,195
Rohrer, J. D., Nicholas, J. M., Cash, D. M., van Swieten, J., Dopper, E., Jiskoot, L., van Minkelen, R., Rombouts, S. A., Cardoso, M. J., Clegg, S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70324-2 · Cited by 538
Self-citationExaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice
Yin, F., Banerjee, R., Thomas, B., Zhou, P., Qian, L., Jia, T., Ma, X., Ma, Y., Iadecola, C., Beal, M. F., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091568 · Cited by 480 · cited 1×
“31 32 35–37 In vitro, progran-ulin seems to have a role of inactivating astrocytes with evidence that progranulin attenuates a pro-inflammatory phenotype of astrocytes.”
Cited by
Biomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
“74,79,80 Concentrations were also elevated in Lewy body dementia compared with both controls and people with Parkinson’s disease.”
Self-citationBlood GFAP as an emerging biomarker in brain and spinal cord disorders
Abdelhak, A., Foschi, M., Abu-Rumeileh, S., Yue, J. K., D’Anna, L., Huss, A., Oeckl, P., Ludolph, A. C., Kuhle, J., Petzold, A., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00616-3 · Cited by 807
Self-citationHansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607
“53,54 Studies have shown that plasma GFAP levels can predict subsequent cognitive change and AD dementia in patients with MCI 52 and cognitive decline in CU subjects.”
BackgroundSelf-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citation
Metadata
- Authors
- Heller, C., Foiani, M. S., Moore, K., Convery, R., Bocchetta, M., Neason, M., Cash, D. M., Thomas, D., Greaves, C. V., Woollacott, I. O., Shafei, R., Van Swieten, J. C., Moreno, F., Sanchez-Valle, R., Borroni, B., Laforce Jr, R., Masellis, M., Tartaglia, M. C., Graff, C., Galimberti, D., Rowe, J. B., Finger, E., Synofzik, M., Vandenberghe, R., de Mendonca, A., Tagliavini, F., Santana, I., Ducharme, S., Butler, C. R., Gerhard, A., Levin, J., Danek, A., Frisoni, G., Sorbi, S., Otto, M., Heslegrave, A. J., Zetterberg, H., & Rohrer, J. D.
- Affiliations
- UK Dementia Research Institute (GB)
- UCL Queen Square Institute of Neurology (GB)
- University of Brescia (IT)
- Sunnybrook Health Science Centre (CA)
- University of Toronto (CA)
- Karolinska University Hospital (SE)
- University of Milan (IT)
- University of Cambridge (GB)
- Western University (CA)
- German Center for Neurodegenerative Diseases (DE)
- KU Leuven (BE)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Coimbra (PT)
- McGill University (CA)
- University of Oxford (GB)
- Ludwig-Maximilians-Universität München (DE)
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- University of Florence (IT)
- Universität Ulm (DE)
- Corresponding author
- Rohrer, Jonathan D
- ORCID
- Heller, Carolin
- Foiani, Martha S
- Moore, Katrina
- Convery, Rhian
- Bocchetta, Martina
- Neason, Mollie
- Cash, David M
- Thomas, David
- Greaves, Caroline V
- Woollacott, Ione OC
- Shafei, Rachelle
- Van Swieten, John C
- Borroni, Barbara
- Masellis, Mario
- Tartaglia, Maria Carmela
- Graff, Caroline
- Galimberti, Daniela
- Rowe, James B
- Finger, Elizabeth
- Synofzik, Matthis
- Vandenberghe, Rik
- Tagliavini, Fabrizio
- Santana, Isabel
- Ducharme, Simon
- Butler, Christopher R
- Levin, Johannes
- Danek, Adrian
- Frisoni, Giovanni
- Sorbi, Sandro
- Otto, Markus
- Heslegrave, Amanda J
- Zetterberg, Henrik
- Rohrer, Jonathan D
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2020-01-14
- Volume
- 91
- Issue
- 3
- Pages
- 263-270
- ISSN
- 0022-3050 (ISSN-L)
- 1468-330X
- OpenAlex
- W3000153083
- Cited by
- 182
- References
- 49
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 26 · 2023: 34 · 2022: 43 · 2021: 30 · 2020: 9
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion, cc-by)
- Lirias (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- DZNE Pub (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Apollo
- Funders
- Bluefield project
- Weston Brain Institute
- ZonMw Memorabel (Deltaplan Dementie, project number 733 051 042)
- Medical Research Council (MR/M008525/1, MR/M018288/1, MR/M023664/1)
- Netherlands Organization for Scientific Research (HCMI 056-13-018)
- Alzheimer Nederland
- Brain Research Trust
- Alzheimer's Research UK (ARUK-CRF2017B-2)
- Stockholm County Council ALF
- Wolfson Foundation (Leonard Wolfson Experimental Neurology Centre)
- Association for Frontotemporal Degeneration
- Hjärnfonden
- National Institute for Health Research (BRC149/NS/MH, Cambridge Biomedical Research Centre, Queen Square Dementia Biomedical Research Unit, UCL/H Biomedical Research Centre)
- Wallenberg Academy (Wallenberg Academy fellowship)
- Swedish FTD Initiative-Schörling Foundation
- Bundesministerium für Bildung und Forschung (FTLDc)
- EU Joint Programme - Neurodegenerative Disease Research (2018-02754, Prefrontals VR Dnr 529-2014-7504, VR: 2015-02926)
- Alzheimer Foundation
- Italian Ministry of Health ((PreFrontALS) grant 733051042, Centres of Excellence in Neurodegeneration grant)
- Institute of Neurosciences, Mental Health and Addiction (327387, Canadian Institutes of Health Research operating g, Centres of Excellence in Neurodegeneration grant)
- Ontario Brain Institute
- Mady Browaeys Fund (Research into Frontotemporal Dementia)
- Association for Frontemporal Dementias Research (Association for Frontemporal Dementias Research Gr)
- Dioraphte Foundation (09-02-03-00)
- Center for Networked Biomedical Research on Neurodegenerative Disease
- Wellcome Trust (103838, Multi-User Equipment Grant)
- Tau Consortium
- UK Dementia Research Institute UCL
- Alzheimer's Society (AS-PG-16-007, PhD studentship)
- Fundació Marató de TV3 (20143810)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- glial fibrillary acidic protein, progranulin, frontotemporal dementia, plasma biomarkers, neurofilament light chain, C9orf72 expansion, MAPT mutations, presymptomatic disease, astrocyte activation, temporal lobe atrophy, disease onset prediction, neurodegeneration
- MeSH terms
- C9orf72 Protein, Progranulins, Adult, Aged, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Mutation, Biomarkers, Case-Control Studies, tau Proteins, Neurofilament Proteins, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. https://app.cochat.ai/papers/10.1136/jnnp-2019-321954
- The paper
- Heller, C., Foiani, M. S., Moore, K., Convery, R., Bocchetta, M., Neason, M., Cash, D. M., Thomas, D., Greaves, C. V., Woollacott, I. O., Shafei, R., Van Swieten, J. C., Moreno, F., Sanchez-Valle, R., Borroni, B., Laforce Jr, R., Masellis, M., Tartaglia, M. C., Graff, C., . . . Rohrer, J. D. (2020). Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2019-321954
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.